Lymphangioleiomyomatosis Clinical Trial
Official title:
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
The primary objective of the MILED trial is to determine if early, long term (2 yr), low dose (fixed at 1 mg/day) treatment of patients with well-preserved lung function will prevent disease progression to more advanced stages. Sixty patients with FEV1>70% predicted will be enrolled and randomized to receive 1 mg/day sirolimus or placebo, and followed for a period of 2 years with pulmonary function testing every 4 months. The primary endpoint will be the between-group (placebo vs. sirolimus) difference in the rate of change in FEV1 (in liters) over two years. Secondary endpoints will include severity grade adverse events, time to 200cc or 10% FEV1 decline, forced vital capacity, lung volumes, diffusing capacity, serum VEGF-D, and early airflow obstruction assessed using hyper-polarized gas MRI. The study will be conducted through the Rare Lung Disease Clinic Network, a confederacy of clinics organized by the LAM Foundation that is currently following over 1300 U.S. LAM patients and conducting the Department of Defense sponsored Trial of an Aromatase Inhibitor in LAM (TRAIL) trial. The LAM Foundation will assist with study recruitment and dissemination of results, and the University of South Florida will function as the Data Coordinating Center. Successful completion of this study will define the safety and efficacy of low dose sirolimus in patients with normal lung function, and determine if sirolimus can be used to prevent disease progression to symptomatic stages. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01687179 -
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
|
Phase 1 | |
| Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
| Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
| Unknown status |
NCT00490789 -
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
|
Phase 2 | |
| Not yet recruiting |
NCT05087134 -
Characterizing LAM With 11C-Choline PET/CT
|
Early Phase 1 | |
| Completed |
NCT02009241 -
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
|
N/A | |
| Recruiting |
NCT05190627 -
Effect of Loratadine in Lymphangioleiomyomatosis
|
Phase 2 | |
| Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
| Completed |
NCT02859194 -
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
|
N/A | |
| Completed |
NCT01353209 -
Letrozole for Lymphangioleiomyomatosis
|
Phase 2 | |
| Completed |
NCT03253913 -
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
|
Phase 2 | |
| Recruiting |
NCT02432560 -
Safety and Durability of Sirolimus for Treatment of LAM
|
||
| Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Recruiting |
NCT04577937 -
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
|
N/A | |
| Completed |
NCT00005906 -
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
|
Phase 2 | |
| Recruiting |
NCT01799538 -
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
| Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|
||
| Enrolling by invitation |
NCT05727852 -
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
|